Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 12/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | CTSS | P25774 | 3/20 | 0.39 |
| ▸ | PLOD2 | O00469 | 1/20 | 0.38 |
| ▸ | PLOD3 | O60568 | 1/20 | 0.38 |
| ▸ | PLOD1 | Q02809 | 1/20 | 0.38 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | FAP | Q12884 | 1/20 | 0.37 |
| ▸ | CTSV | O60911 | 2/20 | 0.36 |
| ▸ | CTSL | P07711 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4041417 | 0.93 | CTSK (0.57) | CTSKCTSSCTSL | |
| SCHEMBL4040030 | 0.92 | CTSK (0.41) | CTSKSMN1; SMN2TP53CTSSPLOD2 | |
| SCHEMBL4041377 | 0.90 | CTSK (0.51) | CTSKSMN1; SMN2TP53CTSSCTSL | |
| SCHEMBL4041900 | 0.90 | CTSK (0.54) | CTSKCTSSPREPFAPCTSV | |
| SCHEMBL4045315 | 0.89 | CTSK (0.53) | CTSKSMN1; SMN2TP53CTSSPREP | |
| SCHEMBL4044028 | 0.89 | CTSK (0.50) | CTSKCTSSPREPFAP | |
| SCHEMBL4040987 | 0.89 | CTSK (0.65) | CTSKCTSSPREPFAPCTSV | |
| SCHEMBL4043349 | 0.88 | CTSK (0.49) | CTSKSMN1; SMN2TP53CTSS | |
| SCHEMBL4040176 | 0.88 | CTSK (0.52) | CTSKCTSSPREPFAPCTSL | |
| SCHEMBL4046916 | 0.88 | CTSK (0.65) | CTSKCTSSPREPFAPCTSV |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885SMN1; SMN2 3546/4885TP53 1281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.